home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  March 03, 2024
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 469 active entries

AlphaVax Human Vaccines, Inc.

710 W. Main St
Durham, NC 27701, USA

Phone: 919-688-6902
Fax: 919-688-7396

Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


AlphaVax, Inc., based in Durham, North
Carolina, has been established to commercialize the proprietary AlphaVax vector system, an innovative vaccine delivery technology. The AlphaVax technology constitutes a major advance in vector technology and presents the opportunity to immunize against diseases not currently preventable with vaccines and to substantially improve existing vaccines. Immediate applications of the vectors include preventative and therapeutic human vaccines for infectious diseases and cancer and the production of vaccine intermediates and therapeutic proteins. AlphaVax is focusing on an aggressive development plan for a vaccine to treat human immunodeficiency virus (HIV) due to the critical need for new preventative measures and accelerated development timelines.

The AlphaVax vectors are derived from an avirulent form of Venezuelan equine encephalitis (VEE) virus, and have multiple distinct advantages over other vaccine technologies. These advantages include:

  1. natural targeting to the antigen-processing cells of the immune system,

  2. high antigen expression levels,

  3. induction of broad and robust humoral, cellular, and mucosal immune responses,

  4. sustained efficacy over multiple simultaneous or sequential inoculations, and

  5. a high margin of safety.

AlphaVax products will target the human vaccine market, which exceeded $3.5 billion in 1996 and is growing at 15% annually. Expansion of this market should be sustained over the next decade as increasing emphasis is placed on preventative medicines by cost-conscious healthcare providers and as technical advances expand the range of diseases which can be prevented through immunization.

Last update of this entry: before October 1999.

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.